October 7, 2020
Willkie represented Relief Therapeutics in the negotiation of a collaboration agreement with NeuroRx, for the commercialization of RLF-100 (Aviptadil), a pharmaceutical treatment with potential applications for the treatment of COVID-19 patients.
Willkie recently represented RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF) in the negotiation of a collaboration agreement with NeuroRx, Inc. for the commercialization of RLF-100™ (Aviptadil) worldwide.
RLF-100 is a pharmaceutical treatment with potential applications for the treatment of COVID-19 patients. More specifically, the drug is believed to inhibit coronavirus replication, block inflammation and remediate COVID-19 patients experiencing acute respiratory distress syndrome. The FDA has granted Investigational New Drug (“IND”) authorization for intravenous and inhaled delivery of RLF-100 for the treatment of COVID-19 and awarded Fast Track designation.
The Willkie deal team was led by partners Robert Rizzo and Heather Schneider and included Tom Meloro, Craig Martin and Spencer Simon.
